EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation

Sara A Murphy, Jiaqi Li, Upasana Sahu, Jessica Swanner, Cole T Lewis, Benedict Anchang, Yan Cui, E Antonio Chiocca, Balveen Kaur

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-013640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Sara A Murphy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: 5'-Nucleotidase, Oncolytic Virotherapy, Macrophages, Antigen Presentation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCR NIH HHS, National Institute of Neurological Disorders and Stroke, National Institute of Dental and Craniofacial Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oncolytic herpes simplex virus (oHSV) therapy is a live virus-based immunotherapy that lyses tumor cells which release antigens and activate antitumor immunity. oHSV therapy has been shown to increase ATP production and release of extracellular ATP (eATP). In the extracellular tumor microenvironment, eATP functions as an immune-activating damage-associated molecular pattern but is hydrolyzed to extracellular adenosine (eADO), which can be immune-suppressive. eADO is generated by the sequential action of ectoenzymes CD39 and CD73 ( NT5E ). Here, we examined the role of immunosuppressive eADO signaling in regulating antitumor immune efficacy of oHSV.

Methods

We evaluated changes in eADO signaling in vitro and in patient specimens after virotherapy. A genetic CD73 knock-out mouse model and blocking antibodies were used to assess the impact of CD73 on virotherapy in two different solid tumor models. Single-cell RNA sequencing was employed to assess changes in immune cell infiltration and communication. Flow cytometric immunophenotyping and immunofluorescent imaging were utilized to confirm single-cell sequencing predicted changes in tumor microenvironment.

Results

Transcriptomic analysis of patient tumors pre-virotherapy and post-virotherapy with CAN-3110 revealed increased expression of the adenosine receptor gene ADORA2B after treatment. High NT5E gene expression, as well as gene signatures suggestive of adenosine signaling, correlated with a significantly worse prognosis for patients with solid tumors. Single-cell sequencing of immune cells recruited to tumor-bearing brain hemispheres in CD73 knockout mice revealed an increase in macrophage-mediated antigen presentation and CD4 + T cell cross-communication. Intracranial tumor-bearing CD73 knock-out mice treated with oHSV showed significant therapeutic improvement as the result of oHSV compared with wild-type mice. Combination of virotherapy with CD73 antibody blockade also resulted in enhanced antitumor efficacy.

Conclusions

Here, we identify that immunosuppressive eADO signaling in the TME is a major barrier to oHSV therapy and CD73 blockade prevents tumor immune escape. The combination of oHSV with CD73 blockade supports the development of an antitumor immune memory response in solid tumors. This study supports clinical development of this combination strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5'-NucleotidaseOncolytic VirotherapyMacrophagesAntigen PresentationOncolytic VirusesNeoplasmsSimplexvirusAnimalsMiceHumansTumor MicroenvironmentMice, KnockoutCell Line, TumorImmunotherapyFemaleGPI-Linked Proteins

Stichwörter der Autor:innen

Combination therapyImmunotherapyOncolytic virusSolid tumorTumor microenvironment - TME

Substanzen

5'-NucleotidaseNT5E protein, humanGPI-Linked Proteins

Autor:innen und Institutionen

  • Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, Texas, USA.
  • Pathology, Augusta University Medical College of Georgia, Augusta, Georgia, USA.
  • Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, North Carolina, USA.
  • Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Neurosurgery, The University of Texas Health Science Center, Houston, Texas, USA.
  • Neurosurgery, LSU Health New Orleans, New Orleans, Louisiana, USA.

Förderung

  • NIDCR NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Dental and Craniofacial Research
  • Cancer Prevention and Research Institute of Texas
  • National Cancer Institute
  • Georgia Cancer Center Paceline Trainee Research Award

Zitieren

APA

Murphy, S. A., Li, J., Sahu, U., Swanner, J., Lewis, C. T., Anchang, B., Cui, Y., Chiocca, E. A., & Kaur, B. (2026). CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013640

Vancouver

Murphy SA, Li J, Sahu U, Swanner J, Lewis CT, Anchang B, et al. CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013640

BibTeX
@article{Murphy2026,
  author = {Murphy, Sara A and Li, Jiaqi and Sahu, Upasana and Swanner, Jessica and Lewis, Cole T and Anchang, Benedict and Cui, Yan and Chiocca, E Antonio and Kaur, Balveen},
  title = {CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-013640}
}
Kostenlos starten →